Jazz Pharmaceuticals (JAZZ) Stock Forecast, Price & News

Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

Is Jazz Pharmaceuticals a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Jazz Pharmaceuticals stock.
View analyst ratings for Jazz Pharmaceuticals or view top-rated stocks.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Jazz Pharmaceuticals.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its quarterly earnings data on Wednesday, May, 4th. The specialty pharmaceutical company reported $3.13 earnings per share for the quarter, topping analysts' consensus estimates of $3.00 by $0.13. The specialty pharmaceutical company had revenue of $813.72 million for the quarter, compared to the consensus estimate of $853.73 million. Jazz Pharmaceuticals had a negative net margin of 13.63% and a positive trailing twelve-month return on equity of 22.45%. Jazz Pharmaceuticals's revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the business earned $3.42 EPS.
View Jazz Pharmaceuticals' earnings history.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.70 billion, compared to the consensus revenue estimate of $3.58 billion.

What price target have analysts set for JAZZ?

12 analysts have issued 12-month target prices for Jazz Pharmaceuticals' stock. Their forecasts range from $174.00 to $250.00. On average, they expect Jazz Pharmaceuticals' share price to reach $208.14 in the next year. This suggests a possible upside of 39.3% from the stock's current price.
View analysts' price targets for Jazz Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the following people:

• Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 58, Pay $2.48M) (LinkedIn Profile)
• Mr. Daniel N. Swisher Jr., Pres (Age 59, Pay $1.37M)
• Ms. Renee D. Gala, Exec. VP & CFO (Age 50, Pay $924.52k)
• Dr. Robert Iannone M.D., Exec. VP of R&D and Chief Medical Officer (Age 55, Pay $1.05M)
• Ms. Kim Sablich, Exec. VP & GM of North America (Age 53, Pay $869.48k) (LinkedIn Profile)
• Mr. Christopher John Tovey BSc, Exec. VP, COO and MD of Europe & International (Age 57)
• Ms. Patricia Carr, VP of Fin. & Principal Accounting Officer (Age 51) (LinkedIn Profile)
• Dr. Finbar Larkin Ph.D., Sr. VP of Technical Operations (Age 64)
• Ms. Andrea N. Flynn Ph.D., VP & Head of Investor Relations
• Ms. Neena M. Patil J.D., Chief Legal Officer and Sr. VP of Legal & Corp. Affairs (Age 46) (LinkedIn Profile)

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Jazz Pharmaceuticals' key competitors?

Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of JAZZ's competitors.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.36%), Vanguard Group Inc. (8.99%), JPMorgan Chase & Co. (5.28%), Wellington Management Group LLP (4.21%), State Street Corp (3.76%) and LSV Asset Management (2.90%). Company insiders that own Jazz Pharmaceuticals stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Elmar Schnee, Finbar Larkin, James E Flynn, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns and Seamus Mulligan.
View institutional ownership trends for Jazz Pharmaceuticals.

Which institutional investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Polar Capital Holdings Plc, Goldman Sachs Group Inc., Renaissance Technologies LLC, Victory Capital Management Inc., Assenagon Asset Management S.A., Bellevue Group AG, and Rhenman & Partners Asset Management AB. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Anne Oriordan, Bruce C Cozadd, Elmar Schnee, Finbar Larkin, Kim Sablich, Mark Douglas Smith, Neena M Patil, and Patricia Carr.
View insider buying and selling activity for Jazz Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was purchased by a variety of institutional investors in the last quarter, including Atika Capital Management LLC, Wellington Management Group LLP, Sumitomo Mitsui Trust Holdings Inc., Woodline Partners LP, Great Point Partners LLC, Loomis Sayles & Co. L P, JPMorgan Chase & Co., and Braun Stacey Associates Inc.. Company insiders that have bought Jazz Pharmaceuticals stock in the last two years include James E Flynn, and Seamus Mulligan.
View insider buying and selling activity for Jazz Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $149.40.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals has a market capitalization of $9.31 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329.67 million in net income (profit) each year or ($7.510010) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

Jazz Pharmaceuticals employs 3,200 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.

When was Jazz Pharmaceuticals founded?

Jazz Pharmaceuticals was founded in 2003.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is www.jazzpharma.com.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at [email protected], or via fax at 353-1634-7850.